Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

60 results about "T-lymphocyte proliferation" patented technology

This behaviour is utilized in T lymphocyte proliferation assays, which can reveal exposure to specific antigens. Sub-populations. Historically, memory T cells were thought to belong to either the effector or central ...

Method for promoting CD4+T proliferation and activation and suppressing Jurkat T cell by using red cassia tree lectin

InactiveCN102226170APromote proliferation and activationPrevent proliferationBlood/immune system cellsGrowth retardantAnti virus
The invention discloses a method for promoting cell proliferation and activation of peripheral blood CD4+T lymphocyte and suppressing cell proliferation and migration of acute lymphocytic leukemia (ALL) Jurkat T cells by using red cassia tree lectin. The separation and purification of red cassia tree lectin from red cassia tree seeds can be carried out at the temperature of 1-5 DEG C during the entire process, the proliferation and activation of the peripheral blood T lymphocyte CD4 subgroup can be promoted by the red cassia tree lectin through the verifications of an MTT (3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide) experiment, a DNA (deoxyribonucleic acid) analysis and an FCM (flow cytometry), and the red cassia tree lectin is CD4+T lymphocyte mitogen more efficient than PHA (Phytohaemagglutinin) and provides a new and effective way for anti-virus infection and vaccine intensifier development; through the verifications of CCK-8 (Cell Counting Kit-8) experiment, DNA analysis, cell apoptosis analysis, ELISA (enzyme-linked immuno sorbent assay) experiments and migration assay, the red cassia tree lectin can obviously suppress the proliferation and migration of the Jurkat T lymphocyte, is a growth inhibitor more efficient for the ALL cells and provides a new and effective supplementary means for treating the hematological malignancies.
Owner:GUANGXI MEDICAL UNIVERSITY

Hyriopsis cumingii enzymolysis polypeptide, as well as preparation and application thereof

The invention provides a Hyriopsis cumingii enzymolysis polypeptide, preparation and application thereof. The enzymolysis method comprises the following steps that: fresh Hyriopsis cumingii meat is crushed and pulped, and added with water of which the weight is 5 to 6 times of that of the fresh Hyriopsis cumingii meat; the mixture is boiled and filtered; the precipitate is dried and degreased to obtain albumen powder of the Hyriopsis cumingii meat; the albumen powder of the Hyriopsis cumingii meat is soaked in water of which the weight is 6 to 8 times of that of the albumen powder of the Hyriopsis cumingii meat for 11 to 12 hours and subjected to superfine grinding and even pulping, and the pH value of the mixed solution is adjusted to between 8.0 and 9.0; based on the albumen content in the albumen powder of the Hyriopsis cumingii meat, 0.3 to 0.6 percent of alkali protease is added in the mixed solution for enzymolysis for 4 to 6 hours at a temperature of between 40 and 60 DEG C; the obtained supernatant is condensed and dried to obtain the Hyriopsis cumingii enzymolysis polypeptide; and by testing, the content of the total albumen of the Hyriopsis cumingii enzymolysis polypeptide is more than or equal to 80 percent, wherein the contents of asparagic acid, glutamic acid, leucine, lysine and arginine are more than or equal to 50 percent, and the molecular weight is mainly concentrated in two zones of 6,100Da and 26,200Da. By a test for culturing mouse lymphocytes in vitro, the Hyriopsis cumingii enzymolysis polypeptide can be used for preparing a medicament for promoting proliferation of the T lymphocute and a health care food for improving the immunity.
Owner:ZHEJIANG GONGSHANG UNIVERSITY

Patch for prevention and control of bronchial asthma

The invention relates to a traditional Chinese medicine patch for the prevention and early-stage curing of bronchial asthma, and the treatment of a plurality of respiratory diseases and megrims, characterized in that the traditional Chinese medicine patch comprises, based on the weight percentage, 57 to 70 % of peach seed, 12 to 25 % of cape jasmine, 6 to 8 % of almond, and 5 to 10% of pepper. The invention has the advantages that the traditional Chinese medicine patch is mainly used for treating bronchial asthma, can cure the bronchial asthma of children at the age of below 12, and can be used in the outbreaking or catabatic period. The traditional Chinese medicine patch has the efficacy of diminishing inflammation, invigorating blood circulation, removing blood stasis, clearing away cold, relieving cough and calming panting. The traditional Chinese medicine patch can promote the synthesis of the alveolar surfactant, protect the pulmonary function to improve the lesion tissues, and can stimulate the proliferation of blood vessel endothelial cells to restore the endangium. The traditional Chinese medicine patch has the antiallergic effect, can inhibit the antiserum reaction of allergic antibody of the skin, reduce the pigment seepage and alleviate the airway obstruction. The traditional Chinese medicine patch can enhance the proliferation and conversion of T lymphocyte of spleen of a body, and improve the autoimmunity.
Owner:凌永玉 +1

Recombinant bacillus subtilis expressing C30 carotenoid

The invention relates to recombinant bacillus subtilis capable of synthesizing carotenoid 4,4'-diaponeurosporene with 30 carbon atoms (C30), and belongs to the biotechnology genetic engineering field. A bacillus subtilis expression plasmid pMK3-crtmn (which is capable of expressing C30 carotenoid synthases Crtm and Crtn in bacillus subtilis) containing C30 carotenoid synthase genes crtm and crtn is successfully constructed, and is successfully electro-transformed into bacillus subtilis WB800. The WB800 strain after transformation turns from the original color of white to yellow. A pigment component extracted from the recombinant WB800 is identified as 4,4'-diaponeurosporene by high performance liquid chromatography (HPLC). 4,4'-diaponeurosporene can stimulate maturation of dendritic cells, and generated cytokines (IL-6, IL-10, IL-12p70 and TNF[alpha]) have the amount increased, and moreover and have stronger ability to stimulate proliferation of T lymphocytes. With oral administration of the bacillus subtilis capable of synthesizing 4,4'-diaponeurosporene, the dextran sulphate sodium (DSS)-induced mice colitis symptoms can be significantly reduced. The bacillus subtilis capable of producing 4,4'-diaponeurosporene is expected to be developed as probiotics for prevention of colitis.
Owner:NANJING AGRICULTURAL UNIVERSITY

Kit used for identifying hematopoietic stem cell transplantation effect

The invention discloses a kit used for identifying hematopoietic stem cell transplantation effect. The kit comprises assemblies A, B, C, D, E, F, G, and H. The assembly A is a substance used for preparing bone marrow mononuclear cells; the assembly B is a substance used for culturing bone marrow mesenchymal stem cells to form colonies; the assembly C is a substance used for counting the bone marrow mesenchymal stem cell colonies; the assembly D is a substance used for identifying whether bone marrow mesenchymal stem cells are capable of being differentiated into osteoblasts; the assembly E is a substance used for identifying whether bone marrow mesenchymal stem cells are capable of being differentiated into adipocytes; the assembly F is a substance used for identifying whether bone marrow mesenchymal stem cells have capacity of inhibiting T lymphocyte proliferation; and the assembly G is a substance used for identifying whether bone marrow mesenchymal stem cells are capable of being feeder cells of hematopoietic stem cells. The kit provided by the invention is convenient and practical, and is simple to operate. The kit can be used for detecting bone marrow hematopoietic microenvironment recovery condition after a hematopoietic stem cell transplantation operation. With the kit, a basis is provided for the researched on mesenchymal stem cells.
Owner:CHINESE PEOPLES LIBERATION ARMY AIR FORCE GENERAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products